Investors

Webcast ImageWebcast
Jaguar Health: Jaguar Animal Health & Napo Pharmaceuticals Merger Update (Live)
Jul 28, 2017 at 8:30 a.m. ET
Jaguar Health: Jaguar Animal Health & Napo Pharmaceuticals Merger Update
Friday, July 28, 2017 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Canalevia™ is Jaguar’s lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company’s lead non-prescription products. Neonorm™ is a standardized botanical extract derived from the Croton lechleri tree. Canalevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs.

Stock Quote
JAGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$0.71
Change (%) Stock is Up 0.02 (2.90%)
Volume234,241
Data as of 07/21/17 3:59 p.m. ET
Refresh quote
Recent NewsMore News >>
Jul 18, 2017Jaguar Neonorm Foal Study Accepted for Publication in Veterinary Journal
Read More
Jul 06, 2017Jaguar Animal Health to Hold Special Meeting of Stockholders July 27, 2017 to Vote Upon the Consummation of its Proposed Merger with Napo Pharmaceuticals, Inc.
Read More
Jun 27, 2017Napo Pharmaceuticals to Present New Crofelemer (Mytesi) Data at International Aids Society Conference on HIV Science
Read More
Jun 14, 2017Jaguar Animal Health’s Neonorm Calf Obtains OMRI Listing and Can Now be Used in Production of Certified Organic Dairy and Beef Cattle
Read More
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Jaguar Animal Health Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print Page Print Page | E-mail Page Email Page | RSS Feeds RSS Feeds | E-mail Alerts Email Alerts | Financial Tear Sheet Financial Tear Sheet